https://mma.prnewswire.com/media/2723253/Perimeter_Medical_Imaging_AI_Inc__Medical_City_Dallas_Hospital_A.jpg Deployment follows participation in pivotal trial of Perimeter's next-gen technology with AI for breast-conserving surgeries Perimeter Medical Imaging AI, Inc.(TSXV: PINK) (OTCQX: PYNKF) (“Perimeter” or the “Company”), a commercial-stage medical technology company, announced today that Medical City Dallas Hospital, an award-winning 899-bed acute care hospital in the Dallas-Fort Worth area, has adopted the company's […]

Data fromGeotab shows that driving speed has a greater impact on EV range than summer heat, especially for larger vehicles on longer trips As summer heatwaves roll in, many electric vehicle (EV) drivers worry about how high temperatures, and heavy air conditioning use, will affect their range. But data from GeotabInc. and its affiliates (“Geotab”),

Xanadu (xanadu.ai), a world leader in photonic quantum computing, and Mitsubishi Chemical, have launched a joint project to use quantum computing for the advancement of new semiconductor chip fabrication technologies. This collaboration aims to discover novel quantum algorithms for simulating quantum processes in extreme ultraviolet (EUV) lithography-a wafer patterning technique utilizing extremely short wavelength light-which

U.S. Gold Corp. (“U.S. Gold,” the “Company,” “we,” “our” or “us”) (Nasdaq: USAU) is pleased to announcethat effective with the U.S. market open on June 30, 2025, the Company was added to the broad-market Russell 3000 Index (the “Russell 3000”) and the small-cap Russell 2000 Index (the “Russell 2000”) as part of the 2025 annual

TE Connectivity plc (NYSE: TEL) will report financial results for the third quarter of fiscal 2025 before trading begins on July 23, 2025. The company will hold a conference call for investors at 8:30 a.m. ET. The conference call may be accessed in the following ways: https://mma.prnewswire.com/media/337029/TE_CONNECTIVITY_plc_LOGO.jpg — AtTE Connectivity's website: investors.te.com — By telephone:

First full-cycle remote IVF protocol aims to make fertility care more affordable and accessible Sama Fertility, a technology-enabled fertility care provider, today announced the launch of SimpleIVF, the first fully at-home, clinically validated IVF and egg freezing protocol in the United States. To date, Sama has raised $3.8 million from SNR Ventures, with additional investment

Bellemeade Re 2022-1 Ltd. (“BMIR 2022-1”) and Bellemeade Re 2022-2 Ltd. (“BMIR 2022-2” together with BMIR 2022-1, as applicable, the “Issuers” and each, an “Issuer”) today announced the early results as of the Early Tender Time (defined below) of its previously announced fixed-price cash tender offers (each an “Offer”) for the purchase of any and

UniFirst Announces Financial Results for the Third Quarter of Fiscal 2025 GlobeNewswire July 02, 2025 WILMINGTON, Mass., July 02, 2025 (GLOBE NEWSWIRE) — UniFirst Corporation (NYSE: UNF) (the “Company,” “UniFirst” or “we”) today reported results for its third quarter ended May 31, 2025 as compared to the corresponding period in the prior fiscal year: Q3

Scholarship supports Five Outstanding Young Women Pursuing STEM Careers The Northern Virginia Technology Council (NVTC), the region's premier trade association representing the technology community, proudly announces the five recipients of the 2025 NVTC Foundation Kilberg Scholarship. Now in its fifth year, the scholarship fund was established in 2021 at the Community Foundation for Northern Virginia

Ready-to-infuse sepsis therapy marks new advancement in time-critical treatment Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, today announced the approval of a novel formulation of the first-of-its-kind, ready-to-infuse formulation of vancomycin, under the brand name TYZAVAN™(Vancomycin Injection, USP), by the US Food and Drug Administration (FDA). https://mma.prnewswire.com/media/1165956/Hikma_Primary_Coral_Logo.jpg TYZAVAN™is a glycopeptide antibacterial indicated for the